Dravet syndrome (DS) is a rare genetic disorder with onset at 1 year of age, one of the most severe forms of epilepsy, which is characterized by a high frequency and severity of seizures, impaired psychoneurological development, disability and high mortality. Timely diagnosis and treatment can significantly alleviate the course of DS and improve the quality of life of patients and their families. Currently, there is an urgent need to increase awareness of pediatric neurologists and primary care physicians about the diagnostic criteria for the timely detection of patients with DS, referral to an epileptologist to confirm the diagnosis and prescribe the necessary therapy. The provisions of the Expert Council’s resolution, which took place on March 14, 2025, are presented.
10 December 2024 in Pediatria. Journal named after G.N. Speransky
Pyruvate dehydrogenase complex deficiency (PDC) is a mitochondrial disease associated with a violation of pyruvate metabolism and leading to a decrease in ATP production. PDC is responsible for the decarboxylation of pyruvate into acetyl-CoA. PDC deficiency can be caused by changes in any of the genes encoding its subunits. The clinical phenotype is very variable, mainly the central nervous system is affected. Diagnosis of the disease can cause significant difficulties due to the rarity of the pathology, the lack of specificity of clinical symptoms and pronounced clinical polymorphism. The purpose of this research was to describe and discuss the clinical, biochemical and genetic data of six recently observed patients with PDC deficiency who were identified in Russia. Authors have analyzed the clinical manifestations of a rare progressive pathology from the group of mitochondrial diseases caused by pathogenic variants of the nuclear X-linked PDHA1 gene (encodes the alpha subunit of pyruvate dehydrogenase) in six patients aged 8 to 120 months old. By the time of examination in the hospital the main clinical symptoms included as follows: delayed psychomotor development, epileptic seizures, severe delay in psychomotor development and - in a single patient - depression of consciousness to coma, the status of epileptic seizures and an unfavorable outcome. In all patients, magnetic resonance imaging (MRI) of the brain revealed changes as follows: cortical atrophy in all 6 patients, basal ganglia lesion in three cases, congenital brain defects in 3 patients and multicystic lesion in a single patient. All children had high lactate levels. Pathogenic variants of the PDHA1 gene were detected in all 6 children and on this basis the diagnosis was confirmed. As a result of treatment, 5 of the 6 children showed moderate positive dynamics as follows: a decrease in the frequency of epileptic seizures and lactate in the blood, improvement in psychomotor development and - in a single patient - a fatal outcome as a result of late diagnosis and rapidly progressing clinical symptoms. Conclusion: Authors have described the clinical characteristics of PDC in recent cases such as: age of manifestation, the disease course nature, results of molecular genetic studies. Clinical polymorphism in patients with this rare pathology was shown as well. The Article may be of great help to pediatricians, neurologists and geneticists in improving the diagnosis of PDC deficiency.
30 April 2026 in Russian Journal of Child Neurology
Progressive Duchenne muscular dystrophy is a severe progressive X-linked hereditary disease caused by mutations in the DMD gene encoding the dystrophin protein. The disease is characterized by early onset of muscle weakness in the proximal limbs, loss of the ability to walk independently, followed by damage to respiratory and cardiac functions, and premature death of patients in the second or third decade of life. Until recently, patients were prescribed only symptomatic treatment aimed at slowing down the progression of the disease. Currently, several pathogenetic drugs have appeared aimed at restoring the synthesis of the dystrophin protein (microdystrophin). One of them, delandistrogen moxparvovec, is gene therapy drug based on a recombinant adeno-associated virus (AAVhr74). The article presents the experience of using Delandistrogen moxparvovec in 17 patients with Duchenne muscular dystrophy aged 5 years 8 months to 9 years and 1 months. Preliminary data indicate a possible slowdown in the progression of the disease, which is manifested in stabilization or improvement of motor functions. In all patients, the use of this drug was safe, there were no adverse events associated with this therapy.
10 December 2024 in Pediatria. Journal named after G.N. Speransky
Subacute sclerosing panencephalitis (SSPE) is a rare complication caused by persistent measles infection and characterized by a decline in cognitive functions and severe motor impairments. Since SSPE is considered a potentially fatal complication of acute measles infection and is typically develops in young individuals especially those infected prior to the age of two years old, special attention must be paid to the implementation of vaccination programs that can prevent severe disease. Thus, the purpose of this research was to present the demographic and clinical characteristics of pediatric patients with SSPE in order to enhance its early diagnosis and to raise the pediatricians' awareness of this serious measles complication. In this series of case reports Authors represent the clinical picture, laboratory and instrumental data of six children with SSPE admitted at the Russian Children's Clinical Hospital with the Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (Moscow, Russia) in Aug. 2022-Aug. 2024. Authors have conducted an analysis of complaints, clinical symptoms, laboratory, neurophysiological and neuroimaging data of 6 patients with SSPE. All patients have undergone cerebrospinal fluid (CSF) analysis, magnetic resonance imaging (MRI) of the brain and video EEG monitoring during both wakefulness and sleep at the time of diagnosis. Currently, there is no specific treatment for SSPE that would either lead to symptom regression or prevent the related disability. Therefore, vaccination remains the only effective means for the SSPE prevention.